Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Paradigm Biopharmaceuticals ( (AU:PAR) ) is now available.
Paradigm Biopharmaceuticals has acquired Proteobioactives Pty Ltd, securing global patent rights for an oral combination therapy of PPS and a COX-2 inhibitor aimed at treating early-stage osteoarthritis in both human and veterinary markets. This acquisition expands Paradigm’s portfolio beyond its current injectable PPS program, allowing the company to target a broader spectrum of osteoarthritis severity. The strategic move aligns with Paradigm’s core iPPS program and offers a complementary asset for market expansion. The acquisition involves milestone payments and focuses initially on the veterinary field, providing a pathway for eventual human clinical development.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd is a late-stage drug development company focused on delivering new therapies to address unmet medical needs, particularly in the area of osteoarthritis. The company is known for its work on pentosan polysulfate sodium (PPS) and is currently focused on completing its phase 3 program for Zilosul® for moderate to severe osteoarthritis.
Average Trading Volume: 875,946
Technical Sentiment Signal: Sell
Current Market Cap: A$112.9M
See more data about PAR stock on TipRanks’ Stock Analysis page.